logo
logo

Versant Ventures Launches Cimeio Therapeutics With $50 Million Series A

Apr 13, 2022•over 3 years ago

Amount Raised

$50 Million

Round Type

series a

Description

Today, Versant Ventures announced the debut of Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies. Versant has made a $50 million Series A commitment to Cimeio, which is the most recent start-up to emerge from the firm’s Ridgeline Discovery Engine in Basel, Switzerland.

Company Information

Company

Versant Ventures

About

Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm’s emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $4.2 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and R&D expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 85 Versant companies have achieved successful acquisitions or IPOs. For more information, please visit www.versantventures.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech